JPMorgan analyst Richard Vosser raised the firm’s price target on Novo Nordisk to DKK 1,200 from DKK 1,100 and keeps an Overweight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- New diabetes drugs altering how patients are treated, WSJ reports
- Novo Nordisk named ‘Catalyst Driven Idea’ at Morgan Stanley
- Novo Nordisk reports 2022 EPS DKK 24.44 vs. DKK 20.74 last year
- Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
- Novo Nordisk announces FDA approval of label update for Rybelsus